Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to easy bruising and bleeding. ITP has an acute, generally self-limiting form that typically affects children and a chronic form that affects adults. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. However, the approval of thrombopoietin-receptor agonists (TPO–RAs), eltrombopag (Promacta) and romiplostim (Nplate), starting in 2008, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment other than immunomodulation. Despite the availability of many effective therapies, a significant proportion of patients exist who are either unresponsive or refractory to available treatments. The late-phase clinical pipeline of ITP comprises a spleen tyrosine kinase (Syk) inhibitor, Tavalisse, and a second-generation oral TPO–RA, avatrombopag, both of which are expected to launch in the next few years. The early-phase ITP pipeline includes mostly immunomodulating agents, such as inhibitors of CD20, CD40, Fc receptors, and Syk signaling. Although there are many available treatments and a sizable emerging therapy pipeline, the ITP landscape has ample scope and market opportunity for development of agents based on novel therapeutic approaches, particularly agents that can target the specific underlying causes of disease.
How will the size of the ITP population change through 2027?
What are key current therapies in the ITP market? What will be their commercial contribution to the ITP market in 2027?
What are the key drug targets emerging from basic and clinical research in ITP? Which emerging therapies do ITP experts consider most promising? How would new therapies influence management of ITP patients?
How are emerging ITP drugs being evaluated, and which are likely to launch by 2027? What commercial impact will they have on the ITP market?
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key Market Access Considerations in Immune Thrombocytopenic Purpura: United States
Key Market Access Considerations in Immune Thrombocytopenic Purpura: EU5
Looking for More?
Key Abbreviations Related to Immune Thrombocytopenic Purpura
Brands, Marketers, and Generic Availability of Key Therapies for Immune Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura Bibliography
Akash Saini, Ph.D.
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market.Previously, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.